

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III FLOT4-AIO study evaluating the effect of neoadjuvant chemotherapy followed by surgery in patients with limited metastatic gastric or GEJ cancer demonstrated statistically significant improvements in \_\_\_\_\_ for patients who received ECF/ECX versus FLOT.
  - a. Progression-free survival
  - b. Overall survival
  - c. Both a and b
2. The Phase III ONO-4538 study evaluating nivolumab versus placebo as salvage treatment after second- or later-line chemotherapy for advanced gastric or GEJ cancer reported an overall survival advantage with nivolumab.
  - a. True
  - b. False
3. Which of the following categories reflects the mechanism of action of claudiximab (IMAB362)?
  - a. Anti-CLDN18.2 antibody
  - b. Anti-HER2 antibody
  - c. Anti-PD-1/PD-L1 antibody
4. The Phase II FAST study evaluating first-line epirubicin/oxaliplatin/capecitabine with or without claudiximab for patients with advanced gastric and GEJ adenocarcinoma demonstrated statistically significant improvements in \_\_\_\_\_ for patients who received claudiximab.
  - a. Progression-free survival
  - b. Overall survival
  - c. Both a and b
5. Which of the following categories reflects the mechanism of action of napabucasin (BBI608)?
  - a. Cancer stem cell pathway inhibitor
  - b. Anti-PD-1/PD-L1 antibody
6. In the Phase III RAINFALL study the addition of ramucirumab to first-line cisplatin with a fluoropyrimidine for metastatic gastric or GEJ cancer failed to improve progression-free or overall survival.
  - a. True
  - b. False
7. A Phase I/II trial is evaluating margetuximab in combination with pembrolizumab for patients with \_\_\_\_\_ advanced HER2-positive gastric or GEJ cancer.
  - a. Previously untreated
  - b. Relapsed or refractory
8. In comparing metastatic to nonmetastatic gastric cancer, which of the following statements is true about the incidence of MSI-high tumors?
  - a. It is higher in the metastatic setting
  - b. It is higher in the nonmetastatic setting
9. The Phase III BRIGHTER trial is evaluating weekly paclitaxel with or without \_\_\_\_\_ for previously treated gastric or GEJ adenocarcinoma.
  - a. Napabucasin
  - b. Nivolumab
  - c. Ramucirumab
10. Results from Cohort 1 of the Phase II KEYNOTE-059 trial of pembrolizumab monotherapy for patients with pretreated advanced gastric/GEJ cancer demonstrated encouraging clinical activity.
  - a. True
  - b. False